News
Progyny (NASDAQ:PGNY) is a company you may not be familiar with, but it is definitely worth a look. Its fundamentals, growth, profitability, and niche...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow As a tech-focused industry Research Analyst, I aim to provide differentiated insights, whether it is for investing, trading,...
News
This article was written by Follow Full time trader and investor. Instead of lengthy and boring articles, I prefer writing concise arguments about value...
News
This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish...
News
Co-authored by Treading Softly. These days, the mindset of “a dollar saved is a dollar earned” rings exceptionally true. Everything from gasoline to eggs...
News
Listen below or on the go on Apple Podcasts and Spotify Steven Cress, head of Quantitative Strategy at Seeking Alpha, discusses the best dividend...
News
Warren Buffett has, from time to time, likened investing to baseball. The one big difference, he has asserted, is that you can choose to...
News
Being majority-owned by the Brazilian state might raise eyebrows among some readers, but Banco do Brasil (OTCPK:BDORY)(“BdB”) has nonetheless registered meaningful outperformance recently versus...
News
Written by Nick Ackerman, co-produced by Stanford Chemist. In the latest UNII Report, BlackRock Floating Rate Income Strategies Fund (NYSE:FRA) once again showed its...
News
Fundamentals Fueled by a profoundly tragic geopolitical event from external forces, gold prices are poised to conclude this week near their highest levels since...
News
Introduction Telecom services haven’t been the best place to be. While the SPDR Communication Services ETF (XLC) has returned 41% since its inception in...
News
Some words get overused to the point that their true meaning is obscured. I’m pretty sure if we could scan all the company mission...
News
Deals and Financings Suzhou MediLink Therapeutics out-licensed global rights (ex-China) for its antibody-drug conjugate candidate against Human Epidermal Growth Factor Receptor 3 (HER3) to...
